MA49839B1 - Inhibiteurs bicycliques de la histone déacétylase - Google Patents

Inhibiteurs bicycliques de la histone déacétylase

Info

Publication number
MA49839B1
MA49839B1 MA49839A MA49839A MA49839B1 MA 49839 B1 MA49839 B1 MA 49839B1 MA 49839 A MA49839 A MA 49839A MA 49839 A MA49839 A MA 49839A MA 49839 B1 MA49839 B1 MA 49839B1
Authority
MA
Morocco
Prior art keywords
bicyclic
histone deacetylase
deacetylase inhibitors
hdac2
hdac
Prior art date
Application number
MA49839A
Other languages
English (en)
Other versions
MA49839A (fr
Inventor
Nathan Fuller
John Lowe
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of MA49839A publication Critical patent/MA49839A/fr
Publication of MA49839B1 publication Critical patent/MA49839B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

L'invention concerne des composés et des sels pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions pharmaceutiques de ceux-ci, qui sont utiles dans le traitement de pathologies associées à l'inhibition de hdac (par exemple, hdac2).
MA49839A 2017-08-07 2018-08-07 Inhibiteurs bicycliques de la histone déacétylase MA49839B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541807P 2017-08-07 2017-08-07
PCT/US2018/045528 WO2019032528A1 (fr) 2017-08-07 2018-08-07 Inhibiteurs bicycliques d'histone désacétylase

Publications (2)

Publication Number Publication Date
MA49839A MA49839A (fr) 2020-06-17
MA49839B1 true MA49839B1 (fr) 2022-05-31

Family

ID=63364199

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49839A MA49839B1 (fr) 2017-08-07 2018-08-07 Inhibiteurs bicycliques de la histone déacétylase

Country Status (23)

Country Link
US (2) US11225475B2 (fr)
EP (1) EP3664802B1 (fr)
JP (1) JP7152471B2 (fr)
KR (1) KR20200037286A (fr)
CN (1) CN111032040B (fr)
AU (1) AU2018313094A1 (fr)
CA (1) CA3071861A1 (fr)
DK (1) DK3664802T3 (fr)
EA (1) EA039417B1 (fr)
ES (1) ES2914355T3 (fr)
HR (1) HRP20220648T1 (fr)
HU (1) HUE058799T2 (fr)
IL (1) IL272479B2 (fr)
LT (1) LT3664802T (fr)
MA (1) MA49839B1 (fr)
MD (1) MD3664802T2 (fr)
MX (1) MX2020001484A (fr)
PL (1) PL3664802T3 (fr)
PT (1) PT3664802T (fr)
RS (1) RS63343B1 (fr)
SG (1) SG11202000970WA (fr)
SI (1) SI3664802T1 (fr)
WO (1) WO2019032528A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3319959T1 (sl) 2015-07-06 2022-02-28 Alkermes, Inc. Hetero-halo inhibitorji histonske deacetilaze
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
MA49839B1 (fr) 2017-08-07 2022-05-31 Alkermes Inc Inhibiteurs bicycliques de la histone déacétylase
EP4074700A4 (fr) * 2019-12-10 2024-02-07 Shionogi & Co Inhibiteur d'histone désacétylase comprenant un groupe hétérocyclique aromatique contenant de l'azote

Family Cites Families (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE4212748A1 (de) 1992-04-16 1993-10-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
WO1996018617A1 (fr) 1994-12-12 1996-06-20 Merck & Co., Inc. Pyridines 2-acylaminees substitutees utilisees comme inhibiteurs de synthase d'oxyde d'azote
GB9500580D0 (en) 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
US5990133A (en) 1995-02-02 1999-11-23 Smithkline Beecham P.L.C. Indole derivatives as 5-HT receptor antagonist
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
US5886186A (en) 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof
CA2249607A1 (fr) 1996-04-03 1997-10-09 Neville J. Anthony Inhibiteurs de transferase de farnesyl-proteine
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
FR2763944B1 (fr) 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
JPH1149676A (ja) 1997-07-31 1999-02-23 Geron Corp ピリジン系テロメラーゼ阻害剤
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
EP1165490B1 (fr) 1999-03-16 2006-08-16 Cytovia, Inc. Inhibiteurs de caspases 2-aminobenzamidiques substitues et leur utilisation
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
ES2261463T3 (es) 2000-08-14 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
CA2421493A1 (fr) 2000-09-06 2002-03-14 Ortho-Mcneil Pharmaceutical, Inc. Methode de traitement des allergies a l'aide de pyrazoles substitues
WO2002026708A1 (fr) 2000-09-27 2002-04-04 Toray Industries, Inc. Composes conenant de l'azote et inhibiteurs de ccr3 contenant ces composes en tant que principe actif
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
JP2004521878A (ja) 2000-12-07 2004-07-22 スィーヴィー　セラピューティクス　インコーポレイテッド Ａｂｃａ−１を上昇させる化合物
EP1353674A1 (fr) 2000-12-29 2003-10-22 Alteon, Inc. Methode de traitement du glaucome ivb
CN1853630A (zh) 2001-02-21 2006-11-01 Nps制药公司 杂多环化合物及其在亲代谢的谷氨酸受体拮抗剂中的应用
EP1408986B1 (fr) 2001-05-08 2008-09-24 Yale University Composes proteomimetiques et procedes correspondants
WO2003042190A1 (fr) 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
EP1467986A1 (fr) 2002-01-17 2004-10-20 Eli Lilly And Company Composes azacycliques en tant que modulateurs de recepteurs d'acetylcholine
JP4167848B2 (ja) 2002-04-10 2008-10-22 広栄化学工業株式会社 ビアリール化合物の製造法
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
WO2004000820A2 (fr) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Monocycles aromatiques utilises comme modulateurs de la kinase
WO2004000318A2 (fr) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Utilisation de certains monocycles a substitution amino en tant que modulateurs de l'activite des kinases
RU2005106871A (ru) 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
EP1567487A4 (fr) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
CA2515544A1 (fr) 2003-02-11 2004-08-26 Kemia Inc. Composes destines au traitement d'une infection virale
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
DK1648879T3 (da) 2003-07-24 2009-02-23 Euro Celtique Sa Heteroaryl-tetrahydropyridyl-forbindelser, der er anvendelige til behandling eller forebyggelse af smerte
TWI287567B (en) 2003-07-30 2007-10-01 Chi Mei Optoelectronics Corp Light-emitting element and iridium complex
WO2005014580A1 (fr) 2003-08-08 2005-02-17 Janssen Pharmaceutica, N.V. Urees pyridyle piperazinyle
US7470807B2 (en) 2003-08-14 2008-12-30 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivatives and use thereof
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP1663953A1 (fr) 2003-09-24 2006-06-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
CA2555402A1 (fr) 2004-02-12 2005-09-01 Celine Bonnefous Amides bipyridyles en tant que modulateurs du recepteur-5 metabotropique du glutamate
JP2007531757A (ja) 2004-03-30 2007-11-08 カイロン コーポレイション 抗癌剤としての置換チオフェン誘導体
DE602005018758D1 (de) 2004-04-01 2010-02-25 Lilly Co Eli Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
ES2325865T3 (es) 2004-07-26 2009-09-22 Eli Lilly And Company Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos.
WO2006044975A2 (fr) 2004-10-19 2006-04-27 Compass Pharmaceuticals Llc Compositions et leur utilisation comme agents antitumoraux
EP1814856A1 (fr) 2004-11-12 2007-08-08 Galapagos N.V. Composés hétéroaromatiques de l'azote qui se lient au site actif d'enzymes de type protéines kinases
JP2008520742A (ja) 2004-11-23 2008-06-19 ピーティーシー セラピューティクス， インコーポレイテッド Ｖｅｇｆ産生の阻害に有用なカルバゾール誘導体、カルボリン誘導体およびインドール誘導体
TW200634003A (en) 2004-12-22 2006-10-01 Astrazeneca Ab Chemical compounds
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
CA2594726C (fr) 2005-01-14 2013-03-19 Chemocentryx, Inc. Sulfonamides d'heteroaryle et ccr2
EP1683796A1 (fr) 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, leur préparation et leur utilisation médicale
WO2006080884A1 (fr) 2005-01-27 2006-08-03 Astrazeneca Ab Nouveaux composes biaromatiques, inhibiteurs du recepteur p2x7
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
EP2527337A1 (fr) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibiteurs de la 11-bêta hydroxystéroïde déshydrogénase de type I
JP2008545624A (ja) 2005-05-13 2008-12-18 チバ ホールディング インコーポレーテッド 金属錯体を含むケラチン繊維を着色するための方法
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Traitement anticancereux
MX2007015002A (es) 2005-06-02 2008-02-15 Bayer Cropscience Ag Derivados de heteroarilo sustituidos con fenilalquilo.
AU2006258101A1 (en) 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2006137772A1 (fr) 2005-06-20 2006-12-28 Astrazeneca Ab Nouvelle forme physique d'oxabispidines n,n-disubstituees
WO2007002313A2 (fr) 2005-06-24 2007-01-04 Bristol-Myers Squibb Company Derives de phenylglycinamide et pyridylglycinamide utiles en tant que anticoagulants
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
WO2007008541A2 (fr) 2005-07-08 2007-01-18 Kalypsys, Inc. Modificateurs d'absorption de cholesterol cellulaire
FR2892412B1 (fr) 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
AU2006312083A1 (en) 2005-11-03 2007-05-18 Merck Sharp & Dohme Corp. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
KR20160067985A (ko) 2005-11-08 2016-06-14 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
WO2007055374A1 (fr) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation Agent therapeutique pour l'osteoporose
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
BRPI0619252A2 (pt) 2005-11-30 2011-09-20 Vertex Pharma inibidores de c-met e seus usos
RU2426731C2 (ru) 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
WO2007087129A2 (fr) 2006-01-12 2007-08-02 Merck & Co., Inc. Derives d’arylamide fluore
EP1973405A4 (fr) 2006-01-12 2011-06-01 Merck Sharp & Dohme Derives d'hydroxyalkymarylamide
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
JP2007283748A (ja) 2006-03-23 2007-11-01 Fujifilm Corp 光記録媒体および可視情報記録方法
LT3412290T (lt) 2006-03-27 2021-04-26 The Regents Of The University Of California Androgeno receptorių moduliatorius, skirtas prostatos vėžio bei su androgeno receptoriais susijusių ligų gydymui
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
JPWO2007125984A1 (ja) 2006-04-28 2009-09-10 日本農薬株式会社 イソキサゾリン誘導体及び有害生物防除剤並びにその使用方法
US20090076009A1 (en) 2006-05-03 2009-03-19 Arnould Jean-Claude Retired Thiazole derivatives and their use as anti-tumour agents
EP2016068A1 (fr) 2006-05-03 2009-01-21 AstraZeneca AB Dérivés de pyrazole et leur emploi en tant qu'inhibiteurs de pi3k
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
WO2007143557A2 (fr) 2006-06-02 2007-12-13 Brandeis University Composés et procédés de traitement des infections parasitaires gastro-intestinales des mammifères
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008005457A2 (fr) 2006-06-30 2008-01-10 Sunesis Pharmaceuticals Inhibiteurs de pyridinonyle pdk1
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
JP2009544611A (ja) 2006-07-20 2009-12-17 メルク エンド カムパニー インコーポレーテッド ヒストン脱アセチル化酵素阻害剤としてのリン誘導体
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
BRPI0714440A2 (pt) 2006-07-21 2013-04-24 Irm Llc composto inibidor de itpkb, uso do mesmo e composiÇço farmacÊutica
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US9102622B2 (en) 2006-07-28 2015-08-11 University Of Connecticut Fatty acid amide hydrolase inhibitors
WO2008016643A2 (fr) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Entités chimiques, compositions et méthodes
WO2008024978A2 (fr) 2006-08-24 2008-02-28 Serenex, Inc. Dérivés de benzène, de pyridine et de pyridazine
WO2008024970A2 (fr) 2006-08-24 2008-02-28 Serenex, Inc. Dérivés de benzène, de pyridine et de pyridazine
CA2663528A1 (fr) 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated Inhibiteurs heterocycliques de c-met et leurs utilisations
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
EP2128134A1 (fr) 2006-11-02 2009-12-02 Shionogi&Co., Ltd. Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
US20080145816A1 (en) 2006-12-15 2008-06-19 Hershey Adrienne A Yankauer suction device
CA2673451C (fr) 2006-12-21 2016-02-09 Nerviano Medical Sciences S.R.L. Derives de pyrazolo-quinazoline substitues, leur procede de preparation et leur utilisation en tant qu'inhibiteurs des kinases
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
JP2008179067A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
JP2008179068A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
PT2114900T (pt) 2007-01-31 2019-01-17 Ym Biosciences Australia Pty Compostos à base de tiopirimidina e as suas utilizações
NZ579635A (en) 2007-03-20 2011-07-29 Curis Inc Fused amino pyridine as hsp90 inhibitors
WO2008115262A2 (fr) 2007-03-20 2008-09-25 Curis, Inc. Inhibiteurs de hsp90 contenant une fraction de liaison de zinc
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
CA2684701A1 (fr) 2007-04-20 2008-10-30 Biolipox Ab Pyrazoles utiles dans le traitement de l'inflammation
WO2008139152A1 (fr) 2007-05-11 2008-11-20 Sentinel Oncology Limited Composés pharmaceutiques contenant un n-oxyde
MX2009013169A (es) 2007-06-03 2010-04-30 Univ Vanderbilt Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos.
MX2009011615A (es) 2007-06-05 2009-11-10 Sanofi Aventis Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados.
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
WO2009022171A1 (fr) 2007-08-13 2009-02-19 Astrazeneca Ab Composés chimiques 1 - 821
WO2009032861A1 (fr) 2007-09-04 2009-03-12 The Scripps Research Institute Pyrimidinyl-amines substituées en tant qu'inhibiteurs de la protéine kinase
US8354383B2 (en) 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
EP2197552B1 (fr) 2007-09-19 2012-11-21 4Sc Ag Nouvelles pyridines tétrahydrofusionnées comme inhibiteurs d'histone deacétylase
NZ584279A (en) 2007-09-19 2011-11-25 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
CA2702950A1 (fr) 2007-10-16 2009-04-23 Northeastern University Procedes et composes permettant la modulation de l'activite cannabinoide
US20090156825A1 (en) 2007-11-26 2009-06-18 Heidebrecht Jr Richard W Fluorescent compounds that bind to histone deacetylase
WO2009078992A1 (fr) 2007-12-17 2009-06-25 Amgen Inc. Composés tricycliques linéaires utilisés comme inhibiteurs de la kinase p38
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
US20110098267A1 (en) 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
WO2009143018A2 (fr) 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009152087A1 (fr) 2008-06-10 2009-12-17 Plexxikon, Inc. Composés hétéroaryles bicycliques et procédés destinés à la modulation de kinases, et des indications pour celle-ci
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
US20110294836A1 (en) 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
WO2009156484A2 (fr) 2008-06-27 2009-12-30 Novartis Ag Composés organiques
JP5309216B2 (ja) 2008-07-11 2013-10-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての４−フェノキシメチルピペリジン類
WO2010007756A1 (fr) 2008-07-14 2010-01-21 塩野義製薬株式会社 Dérivé de pyridine ayant une activité d'inhibition de la ttk
KR20110028661A (ko) 2008-07-15 2011-03-21 노파르티스 아게 Ｄｇａｔ１ 억제제로서의 헤테로아릴 유도체
EP2334636A2 (fr) 2008-09-19 2011-06-22 Pfizer Inc. Dérivés d'acide hydroxamique utiles comme agents antibactériens
KR20110063574A (ko) 2008-09-29 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 항증식성 화합물
WO2010046780A2 (fr) 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
EP2367824B1 (fr) 2008-12-23 2016-03-23 AbbVie Inc. Dérivés de pyrimidine antiviraux
WO2010088574A1 (fr) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles et analogues apparentés en tant que modulateurs de la sirtuine
WO2010111527A1 (fr) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale
WO2010108921A1 (fr) 2009-03-27 2010-09-30 Nerviano Medical Sciences S.R.L. Dérivés de n-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide à titre d'inhibiteurs de kinase mps1
JP2012522748A (ja) 2009-04-01 2012-09-27 ノバルティス アーゲー ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体
US8334315B2 (en) 2009-05-07 2012-12-18 Gruenenthal Gmbh Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
JP2011006408A (ja) 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
JP5586692B2 (ja) 2009-06-08 2014-09-10 ギリアード サイエンシーズ， インコーポレイテッド アルカノイルアミノベンズアミドアニリンｈｄａｃインヒビター化合物
WO2010151747A1 (fr) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Composés de pyramine ainsi que leurs procédés de fabrication et d'utilisation
WO2011008931A2 (fr) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CA2781888C (fr) 2009-12-11 2019-06-18 Nono Inc. Agents et methodes de traitement de maladies ischemiques et d'autres maladies
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
WO2011082400A2 (fr) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
WO2011119869A1 (fr) 2010-03-24 2011-09-29 Medical University Of South Carolina Compositions et méthodes destinées au traitement de maladies neurodégénératives
BR112012025242B1 (pt) 2010-04-06 2018-04-17 Nippon Soda Co., Ltd. Método para produção de um derivado de amino-6- metilpiridino-n-óxido substituído
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
EP2590968A1 (fr) 2010-07-06 2013-05-15 Novartis AG Composés éthers cycliques utiles comme inhibiteurs de kinase
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2606056A4 (fr) 2010-08-20 2014-01-08 Harvard College Complexes de fluorure de palladium de valence élevée et leurs utilisations
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
WO2012061337A1 (fr) 2010-11-02 2012-05-10 Exelixis, Inc. Modulateurs de fgfr2
CN103402515B (zh) 2010-11-09 2017-05-17 铁木医药有限公司 sGC刺激剂
WO2012074050A1 (fr) 2010-12-01 2012-06-07 富士フイルム株式会社 Film polymère, film de différence de phase, plaque de polarisation, dispositif d'affichage à cristaux liquides et composé
US9427482B2 (en) 2010-12-21 2016-08-30 Koninklijke Philips N.V. Agents for clearing biomolecules from circulation
CN103429571A (zh) 2010-12-22 2013-12-04 普渡制药公司 作为钠通道阻断剂的取代吡啶
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CN103339110A (zh) 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
US8957066B2 (en) * 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CA2831978A1 (fr) 2011-03-03 2012-09-07 Universitat Des Saarlandes Derives biaryle en tant qu'inhibiteurs selectifs de la 17beta-hydroxysteroide deshydrogenase de type 2
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
JP6033835B2 (ja) 2011-03-18 2016-11-30 ルピン アトランティス ホールディングス エスエー カルシウム感知受容体モジュレーターとしてのベンゾ［ｂ］［１，４］オキサジン誘導体
WO2012147890A1 (fr) 2011-04-27 2012-11-01 持田製薬株式会社 Nouveau dérivé d'azole
WO2012149540A1 (fr) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibiteurs de l'histone désacétylase
WO2012154880A1 (fr) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Régulateurs de protéostasie pour le traitement de la mucoviscidose et autres maladies de mauvais repliement des protéines
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6482273B2 (ja) 2011-05-16 2019-03-13 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 生体直交型薬物活性化
PT2713722T (pt) 2011-05-31 2017-06-27 Receptos Llc Novos estabilizadores e moduladores do receptor glp-1
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
JP2014521616A (ja) 2011-07-26 2014-08-28 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換ヘテロ芳香族ピラゾール含有カルボキサミドおよび尿素誘導体
AU2012289255A1 (en) 2011-07-26 2014-01-30 Grunenthal Gmbh Substituted heterocyclic aza derivatives
WO2013017480A1 (fr) 2011-07-29 2013-02-07 Cellzome Limited Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
CN103827092A (zh) 2011-08-12 2014-05-28 巴斯夫欧洲公司 N-硫代邻氨基苯甲酰胺化合物及其作为农药的用途
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
CN103929964A (zh) 2011-09-23 2014-07-16 拜耳知识产权有限责任公司 4-取代的1-苯基吡唑-3-甲酸衍生物作为对抗非生物植物胁迫的活性物质的用途
ES2572908T3 (es) 2011-10-14 2016-06-03 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
WO2013059648A1 (fr) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. Dérivés aminés d'hétéroaryle et d'aryle 2,3,5 trisubstitués, compositions et procédés d'utilisation associés
US9388137B2 (en) 2011-10-31 2016-07-12 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9321763B2 (en) 2012-04-04 2016-04-26 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
CN104245714B (zh) 2012-04-12 2017-09-26 港大科桥有限公司 供oled应用的铂(ii)络合物
US20150105433A1 (en) 2012-04-27 2015-04-16 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
BR112014029501B1 (pt) 2012-05-31 2020-05-19 Sumitomo Chemical Co composto heterocíclico fundido, seu uso, agente de controle de pragas e método para o controle de pragas
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CN104718201A (zh) 2012-06-12 2015-06-17 艾伯维公司 吡啶酮和哒嗪酮衍生物
CN106905297A (zh) 2012-06-15 2017-06-30 加利福尼亚大学董事会 用于脑癌的新颖治疗剂
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
WO2014005125A2 (fr) 2012-06-29 2014-01-03 Biotium, Inc. Composés fluorescents et utilisation de ceux-ci
JP6483610B2 (ja) 2012-07-18 2019-03-13 ユニバーシティ オブ ノートルダム デュ ラック ５，５−ヘテロ芳香族抗感染症化合物
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014025808A1 (fr) 2012-08-06 2014-02-13 The General Hospital Corporation Analogues de curcumine
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CN104837832B (zh) 2012-10-05 2019-04-26 里格尔药品股份有限公司 Gdf-8抑制剂
WO2014056620A1 (fr) 2012-10-11 2014-04-17 Grünenthal GmbH Prévention et/ou traitement des maladies et/ou troubles induits par tspo
JP2014101353A (ja) 2012-10-26 2014-06-05 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
CA2889892A1 (fr) 2012-11-09 2014-05-15 Indiana University Research And Technology Corporation Nouvelles utilisations d'effecteurs d'assemblage du vhb
WO2014081300A1 (fr) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Liposomes activables par des protéines de canal
WO2014081299A1 (fr) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Liposome pouvant être actif
EP2922574B1 (fr) 2012-11-22 2023-05-17 Tagworks Pharmaceuticals B.V. Groupe clivable par voie chimique
US20150297741A1 (en) 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
US9062068B2 (en) 2012-12-04 2015-06-23 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
CN103864754B (zh) 2012-12-10 2016-12-21 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
JP6511430B2 (ja) 2013-03-11 2019-05-15 ザ・ブロード・インスティテュート・インコーポレイテッド がんの治療のための化合物および組成物
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014153208A1 (fr) 2013-03-14 2014-09-25 Epizyme, Inc. Inhibiteurs d'arginine méthyltransférase et leurs utilisations
EP2968339A4 (fr) 2013-03-15 2017-02-15 Celgene Avilomics Research, Inc. Inhibiteurs mk2 et utilisations associées
CN105228997B (zh) 2013-03-15 2018-03-27 Epizyme股份有限公司 Carm1抑制剂及其用途
CN105308020B (zh) 2013-03-20 2018-01-26 豪夫迈·罗氏有限公司 脲衍生物及其作为脂肪酸结合蛋白(fabp)抑制剂的用途
WO2014181287A1 (fr) 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
CN104163791B (zh) 2013-05-20 2017-05-03 湖南化工研究院 N‑吡啶（杂）芳酰胺类化合物及其制备方法与应用
CN104163792B (zh) 2013-05-20 2017-04-12 湖南化工研究院 N‑吡啶酰胺类化合物及其制备方法与应用
WO2014190199A1 (fr) 2013-05-24 2014-11-27 The California Institute For Biomedical Research Composés pour le traitement de la tuberculose résistante aux médicaments et persistante
CA2913622A1 (fr) 2013-05-30 2014-12-04 Washington University Composes et methodes de traitement d'infections bacteriennes
JP6603445B2 (ja) 2013-06-10 2019-11-06 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティー 改変された発光スペクトルを有する蛍光性四座配位金属錯体
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
GB2516303A (en) 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
WO2015031725A1 (fr) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Imidation d'arènes catalysée par des métaux de transition
MX2016002795A (es) 2013-09-06 2016-05-26 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
US9663508B2 (en) 2013-10-01 2017-05-30 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
EP3578176A1 (fr) 2013-10-08 2019-12-11 Lu, Qing-Bin Composés anticancéreux non à base de platine destinés à être utilisés dans la chimiothérapie ciblée
WO2015061247A2 (fr) 2013-10-21 2015-04-30 Merck Patent Gmbh Composés hétéroaryle servant d'inhibiteurs de la btk et leurs utilisations
US9844542B2 (en) 2013-11-19 2017-12-19 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
CN103601718A (zh) 2013-12-05 2014-02-26 江西天人生态股份有限公司 一类基于鱼泥丁受体的邻甲酰氨基苯甲酰胺衍生物及其制备方法和用途
WO2015110999A1 (fr) 2014-01-24 2015-07-30 Piramal Enterprises Limited Inhibiteurs de ezh2 et leurs utilisations
CN103804312B (zh) 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
WO2015142903A2 (fr) 2014-03-17 2015-09-24 Genentech, Inc. Procédé pour réguler la production de lactate à l'aide de dérivés de pipéridine-dione
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
GB201405002D0 (en) 2014-03-20 2014-05-07 Isis Innovation Fluorination method
DK3129350T3 (da) 2014-04-09 2021-11-22 Lumiphore Inc Makrocyklusser
WO2015170218A1 (fr) 2014-05-07 2015-11-12 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
US10065948B2 (en) * 2014-06-02 2018-09-04 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2016018795A1 (fr) 2014-07-28 2016-02-04 The General Hospital Corporation Inhibiteurs d'histone désacétylase
AU2015299161A1 (en) 2014-08-04 2017-03-16 Fundacion Para La Investigacion Medica Aplicada Novel compounds for use in cognition improvement
EP3183255B1 (fr) 2014-08-18 2023-07-05 Hudson Biopharma Inc. Spiropyrrolidines utiles en tant qu'inhibiteurs de mdm2
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
EP3204006A4 (fr) 2014-10-08 2018-04-04 Regenacy Pharmaceuticals, LLC Induction de gata2 par des inhibiteurs de hdac1 et hdac2
CN117024501A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
WO2016058544A1 (fr) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
WO2016100711A1 (fr) 2014-12-18 2016-06-23 The Broad Institute, Inc. Modulateurs de métabolisme des lipoprotéines hépatiques
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
EP3259264B1 (fr) 2015-02-20 2022-07-27 Rigel Pharmaceuticals, Inc. Inhibiteurs du gdf 8
CN106083823A (zh) 2015-04-30 2016-11-09 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
WO2016176657A1 (fr) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Analogues de la mitragynine et leurs utilisations
WO2016183266A1 (fr) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Agents antiviraux de l'hépatite b
SI3319959T1 (sl) 2015-07-06 2022-02-28 Alkermes, Inc. Hetero-halo inhibitorji histonske deacetilaze
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
WO2017027984A1 (fr) 2015-08-20 2017-02-23 Simon Fraser University Composés et procédés de traitement anticancéreux par l'inhibition d'atg4b et le blocage de l'autophagie
US10980755B2 (en) 2015-09-10 2021-04-20 The Regents Of The University Of California LRH-1 modulators
WO2017046133A1 (fr) 2015-09-14 2017-03-23 Universiteit Antwerpen Procédé pour le clivage catalytique dirigé de composés contenant un amide
US20180312493A1 (en) 2015-11-04 2018-11-01 Simon Fraser University Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
HUE049228T2 (hu) 2016-02-23 2020-09-28 Taiho Pharmaceutical Co Ltd Új kondenzált pirimidin vegyület vagy annak sója
DK3426654T3 (en) 2016-03-09 2022-01-03 Harvard College Direct palladium-catalyzed aromatic fluorination
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7175888B2 (ja) 2016-11-23 2022-11-21 リージェナシー・ファーマシューティカルズ・インコーポレイテッド 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
CN106946890A (zh) 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
MA49839B1 (fr) 2017-08-07 2022-05-31 Alkermes Inc Inhibiteurs bicycliques de la histone déacétylase
EA202190070A1 (ru) 2018-07-13 2021-10-26 Алкермес, Инк. Бициклические ингибиторы гистондеацетилазы
MA53129A (fr) 2018-07-13 2021-05-19 Alkermes Inc Inhibiteurs de l'histone désacétylase

Also Published As

Publication number Publication date
CN111032040A (zh) 2020-04-17
IL272479B1 (en) 2023-04-01
AU2018313094A1 (en) 2020-02-20
IL272479B2 (en) 2023-08-01
ES2914355T3 (es) 2022-06-09
JP2020530019A (ja) 2020-10-15
EA202090424A1 (ru) 2020-05-26
CA3071861A1 (fr) 2019-02-14
SG11202000970WA (en) 2020-02-27
WO2019032528A8 (fr) 2019-03-21
MA49839A (fr) 2020-06-17
PT3664802T (pt) 2022-05-24
KR20200037286A (ko) 2020-04-08
MX2020001484A (es) 2020-08-20
DK3664802T3 (en) 2022-05-30
HUE058799T2 (hu) 2022-09-28
US11225475B2 (en) 2022-01-18
MD3664802T2 (ro) 2022-07-31
US11912702B2 (en) 2024-02-27
EA039417B1 (ru) 2022-01-25
SI3664802T1 (sl) 2022-10-28
US20220340558A1 (en) 2022-10-27
JP7152471B2 (ja) 2022-10-12
HRP20220648T1 (hr) 2022-09-02
US20210147410A1 (en) 2021-05-20
IL272479A (en) 2020-03-31
WO2019032528A1 (fr) 2019-02-14
LT3664802T (lt) 2022-06-27
EP3664802B1 (fr) 2022-02-23
RS63343B1 (sr) 2022-07-29
EP3664802A1 (fr) 2020-06-17
PL3664802T3 (pl) 2022-07-11
CN111032040B (zh) 2023-08-29

Similar Documents

Publication Publication Date Title
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MA40290A1 (fr) Agents immunorégulateurs
EA202090871A1 (ru) Ингибирование убиквитин-специфической пептидазы 30
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
EA201792028A1 (ru) Альфа-цинамидные соединения и композиции как ингибиторы hdac8
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
BR112019025049A2 (pt) Anéis 6- 5 fundidos como inibidores de c5a
MA54386B1 (fr) Modulateurs de trex1
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
BR112019025230A2 (pt) Anéis 5-5 fundidos como inibidores de c5a
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA202192118A1 (ru) Фармацевтическая композиция, содержащая ацетаминофен и ибупрофен
EA202190077A1 (ru) Ингибиторы гистондеацетилазы
EA202092190A1 (ru) Композиции и способы для лечения сильного запора
UY38133A (es) Nuevos inhibidores de cdk8/19